Wiley Matthew T.
SEC insider (Form 3/4/5 filer). CIK 0001759703. Chief Commercial Officer at Definium Therapeutics, Inc. (DFTX) and 1 other issuer. 13 reported Form 4/5 transactions since Sep 2024; latest on Sep 25, 2026. Located in NEW YORK, NY.
Companies Wiley Matthew T. has filed insider reports for
- Definium Therapeutics, Inc. (DFTX): Officer, Chief Commercial Officer
- BioXcel Therapeutics, Inc. (BTAI): Officer, Chief Commercial Officer
Wiley Matthew T.
CIK: 0001759703
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Sep 25, 2026DFTX
Definium Therapeutics, Inc.
SaleDirect3.1K shares at avg. $36.57$113K - Sep 14, 2026DFTX
Definium Therapeutics, Inc.
AwardDirect125K shares- - Aug 12, 2026DFTX
Definium Therapeutics, Inc.
AwardDirect62.5K shares- - Jun 25, 2026DFTX
Definium Therapeutics, Inc.
SaleDirect2.9K shares at avg. $45.03$129K - Jun 22, 2026DFTX
Definium Therapeutics, Inc.
AwardDirect62.5K shares- - Feb 3, 2026DFTX
Definium Therapeutics, Inc.
AwardDirect115K shares- - Mar 17, 2025MNMD
Mind Medicine (MindMed) Inc.
AwardDirectStock Option (Right to Buy)
350K shares- - Oct 3, 2024BTAI
BioXcel Therapeutics, Inc.
SaleDirect6.3K shares at avg. $0.55$3K - Sep 17, 2024BTAI
BioXcel Therapeutics, Inc.
AwardDirect21.3K shares- - Sep 16, 2024BTAI
BioXcel Therapeutics, Inc.
SaleDirect215 shares at avg. $0.69$148.522
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 25, 2026 |  DFTX Definium Therapeutics, Inc. | Sale | 3,097 | $36.57 | $113,257 | Direct |
| Sep 14, 2026 | DFTX Definium Therapeutics, Inc. | Award | 125,000 | - | $0 | Direct |
| Aug 12, 2026 | DFTX Definium Therapeutics, Inc. | Award | 62,500 | - | $0 | Direct |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Sale | 2,867 | $45.03 | $129,101 | Direct |
| Jun 22, 2026 | DFTX Definium Therapeutics, Inc. | Award | 62,500 | - | $0 | Direct |
| Feb 3, 2026 | DFTX Definium Therapeutics, Inc. | Award | 115,000 | - | $0 | Direct |
| Mar 17, 2025 |  MNMD Mind Medicine (MindMed) Inc. | Award Stock Option (Right to Buy) | 350,000 | - | - | Direct |
| Oct 3, 2024 |  BTAI BioXcel Therapeutics, Inc. | Sale | 6,272 | $0.55 | $3,450 | Direct |
| Sep 17, 2024 | BTAI BioXcel Therapeutics, Inc. | Award | 21,250 | - | $0 | Direct |
| Sep 16, 2024 | BTAI BioXcel Therapeutics, Inc. | Sale | 215 | $0.69 | $149 | Direct |
1-10 of 13 transactions